A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed

Journal of Thoracic Oncology

Volumn 6, Issue 3, 2011, Pages 624-626

  D'Angelo, Sandra P ^a,b   Kris, Mark G ^a   Pietanza, Maria Catherine ^a   Rizvi, Naiyer A ^a   Azzoli, Christopher G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bilateral lower extremity edema; Chemotherapy toxicities; Lung adenocarcinoma; Pemetrexed

Indexed keywords

BEVACIZUMAB; CEFALEXIN; CETUXIMAB; CISPLATIN; CORTICOSTEROID; FUROSEMIDE; PACLITAXEL; PEMETREXED; PREDNISONE;

AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CASE STUDY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; LOW DRUG DOSE; LUNG ADENOCARCINOMA; MALE; PERIPHERAL EDEMA; PRIORITY JOURNAL; THORAX CANCER;

EID: 79951742820     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318207f788     Document Type: Article

References (7)

1. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002;20:3533-3544.
2. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-380. (Pubitemid 29455582)
3. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced nonsmall- cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:1194.
4. Bastos DA, Calabrich A, Katz A. Pemetrexed-induced fluid retention. J Thorac Oncol 2010;5:752.
5. Kurata T, Tamura K, Okamoto I, et al. Pemetrexed-induced edema of the eyelid. Lung Cancer 2006;54:241-242. (Pubitemid 44764924)
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
7. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998;16:3426-3432. (Pubitemid 28481642)